🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Skin Melanoma

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma NCT04594187Phase 23 sites📍 Jacksonville📍 Camden📍 Houston M.D. Anderson Cancer Center · Tests: Immunotherapy, Quality-of-Life Assessment, Radiation Therapy An International Study on Pediatric Patients With Rare Tumors. NCT07072143n/a1 site📍 Padova Azienda Ospedaliera di Padova Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma NCT07704918NA1 site📍 Aurora University of Colorado, Denver · Tests: Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evol… DermaSensor Postmarket Surveillance Study NCT06666790NA2 sites📍 New Smyrna Beach📍 Morehead City DermaSensor, Inc. · Tests: Scan with elastic scattering spectroscopy device to assess risk of malignancy A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma NCT06581406Phase 2, Phase 333 sites📍 Scottsdale📍 La Jolla📍 Los Angeles Replimune, Inc. · Tests: RP2, Ipilimumab, Nivolumab A Study of IBI363 in Subjects With Advanced Melanoma NCT06081920Phase 212 sites📍 Beijing📍 Beijing📍 Fuzhou Innovent Biologics (Suzhou) Co. Ltd. · Tests: IBI363 Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia NCT07422779NA1 site📍 Ljubljana Institute of Oncology Ljubljana · Tests: Pembrolizumab, Nivolumab, Ipilimumab A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients NCT01638676Phase 1, Phase 21 site📍 Louisville University of Louisville · Tests: Vemurafenib, Metformin Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies NCT06508775NA7 sites📍 Berlin📍 Cologne📍 Erlangen Miltenyi Biomedicine GmbH · Tests: MB-CART19.1, MB-CART20.1, MB-CART2019.1 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors NCT07760012NA1 site📍 Beijing Peking University Third Hospital · Tests: 68Ga-SorB PET/CT Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma NCT07627698Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide COmparison of the Use of a PERforator Flap Versus Total Skin GRAft in the Management of Loss of Substance After Resection of Cutaneous Melanoma - Pilot Study NCT07354152n/a1 site📍 Nantes Nantes University Hospital The MELAcare Study: A New Method for Surveillance of Melanoma Patients NCT05253872NA1 site📍 Copenhagen Herlev and Gentofte Hospital · Tests: The MelaCare intervention Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma NCT05830058Phase 22 sites📍 Duarte📍 Irvine City of Hope Medical Center · Tests: Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Stereotactic B… Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade NCT07661966NA1 site📍 New York Weill Medical College of Cornell University · Tests: Bright Light Therapy Safety and Efficacy of OBX-115 in Advanced Solid Tumors NCT06060613Phase 1, Phase 210 sites📍 Los Angeles📍 Los Angeles📍 Stanford Obsidian Therapeutics, Inc. · Tests: OBX-115 A Study of TRK-950 in Patients With Advanced Solid Tumors NCT05423262Phase 1, Phase 210 sites📍 Nagoya📍 Fukuoka📍 Sapporo Toray Industries, Inc · Tests: TRK-950, TRK-950, TRK-950, Nivolumab, TRK-950 Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma NCT07349303Phase 21 site📍 Gothenburg Vastra Gotaland Region · Tests: Pembrolizumab, Placebo Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System NCT07870265NA1 site📍 Brno Masaryk Memorial Cancer Institute · Tests: Novel CRISPR/Cas12a Electrochemical Bioassay, Reference Standard Molecular Diagnostics (NGS and ddPCR), Serial Peripher… Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention NCT07649681NA6 sites📍 Augsburg📍 Erlangen📍 München Wuerzburg University Hospital · Tests: Gustabor server, Standard Recommendations MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. NCT07092670n/a10 sites📍 Bari📍 Genova📍 Milan Intergruppo Melanoma Italiano · Tests: Dabrafenib + Trametinib, Pembrolizumab, Nivolumab, Observation To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma NCT06204991Phase 12 sites📍 Herlev📍 Herlev Inge Marie Svane · Tests: ADP-TILIL7, Cyclophosphamide, Fludarabine Phosphate, Proleukin Liquid Biopsy Multi-Omics and Biomarker Development in Melanoma NCT07584291n/a1 site📍 Xi'an Xijing Hospital Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study NCT07050940NA5 sites📍 Bari📍 Torino📍 Bari Azienda Ospedaliera di Perugia · Tests: Postbiotic, AntiPD1 A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680Phase 258 sites📍 San Francisco📍 Aurora📍 Atlanta Bristol-Myers Squibb · Tests: BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma NCT07068074Phase 3181 sites📍 Birmingham📍 Daphne📍 Fairhope ECOG-ACRIN Cancer Research Group · Tests: Adjuvant Therapy, Comprehensive Geriatric Assessment, Computed Tomography, Positron Emission Tomography, Questionnaire … A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors NCT04771520Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Avapritinib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy